CombiMatrix Announces Macrogen as Manufacturing/Distribution Partner in Korea and as Purchaser of Synthesizer Systems
CombiMatrix's strategy for the research and development market is to establish manufacturing and distribution relationships with regional companies to enable them to manufacture arrays onsite for their local markets. Each new partner is required to purchase a number of CustomArray Synthesizers. CombiMatrix benefits by the sales of its products and by expanding the commercial market for its products without having to build additional infrastructure. CombiMatrix will continue to sell blank CustomArrays, reagents, additional synthesizers, and equipment to the partner for its local customers. CombiMatrix's proprietary semiconductor technology enables the execution of this business strategy. Other major array manufacturers are not able to execute this business strategy since their manufacturing methods do not enable distributed manufacturing.
“Our strategy for the research and development market of establishing partners that purchase instruments for the manufacturing and distribution of CustomArrays is growing”
"Macrogen has been partnering with the world's leading biotechnology companies and organizations to become the powerhouse of revolutionizing research in Asia. In Korea, we have been very fortunate to lead this effort by utilizing our core technologies in sequencing, microarrays, especially in array CGH, and mouse models to study human diseases. I am personally very excited to be an exclusive manufacturer and distributor in Korea and a global service provider of CombiMatrix, of which in my mind is the most exciting microarray technology yet to be commercialized in the world," said Byung-Hwa Lee, CEO of Macrogen. "The main strength of CombiMatrix's technology is its flexible and easy to use platform that allows a rapid adaptation of new biological contents to be diagnosed within days instead of months. This kind of plasticity was missing until now in all other microarray technologies, and working with CombiMatrix will enable Macrogen to better position itself as a leader in diagnostic microarray market," said Dr. Jason Kang, CTO of Macrogen.
"Our strategy for the research and development market of establishing partners that purchase instruments for the manufacturing and distribution of CustomArrays is growing," said Dr. Amit Kumar, President and CEO of CombiMatrix. "Macrogen has great expertise in Korea and around the world, and it has great expertise in a wide variety of areas, including arrays, array services, and bioinformatics. I also very much like that Macrogen is an aggressive company, working intelligently and aggressively to expand its markets and its offerings. We and Macrogen view the growing role of microarrays in the world -- in R&D, infectious-disease monitoring and tracking, and diagnostics -- as one of enormous opportunity."
ABOUT MACROGEN INC.
Macrogen is Korea's leading biotechnology company, which started out as a lab venture company in Seoul National University in 1997. Macrogen's core businesses include DNA sequence analysis, manufacture of and experiment on biochips, and production of genetically engineered mice (GEM). Macrogen is recognized for its industry-leading genomic information analysis technology and as a global service provider of sequencing services and expression profiling incorporating Applied Biosystems' cutting-edge technologies. Macrogen's DNA sequence analysis service includes the analysis of DNA sequences of various genetic samples from as many as 60 countries worldwide as well as comprehensive genetic analysis services ranging from whole genome projects to genotyping. Its high speed, high quality, and capability to handle various samples make the DNA sequence analysis of Macrogen second to none, thanks to the optimized process developed by the company. Another strength is its capability to manage the entire process of DNA analysis efficiently backed by its homegrown laboratory information management system (LIMS).
Macrogen has been recently selected as an awardee of a five-year grant by the Korean Center for Disease Control as a head research center for developing diagnostic DNA microarrays from various human diseases such as prenatal genetic diseases and cancers.
Macrogen has produces world-class research products. It has acquired first and second animal patents, completed the Korea genome project for the first time in the world in 2001, and developed special strain producing alcohol using Zymomonas mobilis (2005. Nature Biotechnology) as well as unique DNA chip technology used to create a 'fatherless mice'(2004. Nature).
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 47 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.
Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.